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Abstract
Background
Published evidence on treatment costs of breast cancer varies widely in methodology and a
global systematic review is lacking.
Objectives
This study aimed to conduct a systematic review to compare treatment costs of breast can-
cer by stage at diagnosis across countries at different levels of socio-economic develop-
ment, and to identify key methodological differences in costing approaches.
Data sources
MEDLINE, EMBASE, and NHS Economic Evaluation Database (NHS EED) before April
2018.
Eligibility criteria
Studies were eligible if they reported treatment costs of breast cancer by stage at diagnosis
using patient level data, in any language.
Study appraisal and synthesis methods
Study characteristics and treatment costs by stage were summarised. Study quality was
assessed using the Drummond Checklist, and detailed methodological differences were fur-
ther compared.
Results
Twenty studies were included, 15 from high-income countries and five from low- and mid-
dle-income countries. Eleven studies used the FIGO staging system, and the mean treat-
ment costs of breast cancer at Stage II, III and IV were 32%, 95%, and 109% higher than
Stage I. Five studies categorised stage as in situ, local, regional and distant. The mean
treatment costs of regional and distant breast cancer were 41% and 165% higher than local
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breast cancer. Overall, the quality of studies ranged from 50% (lowest quality) to 84% (high-
est). Most studies used regression frameworks but the choice of regression model was
rarely justified. Few studies described key methodological issues including skewness, zero
values, censored data, missing data, and the inclusion of control groups to estimate dis-
ease-attributable costs.
Conclusions
Treatment costs of breast cancer generally increased with the advancement of the disease
stage at diagnosis. Methodological issues should be better handled and properly described
in future costing studies.
Introduction
Breast cancer is the most common cancer among women worldwide, contributing more than
25% of the global new female cancer cases [1]. It is also the first leading cause of female cancer
mortality, accounting for 14.7% of cancer deaths [1].
Breast cancer is a potentially curable disease if diagnosed and treated at an early stage. Sur-
veillance, Epidemiology, and End Results (SEER) Program has reported that breast cancer
cases diagnosed at an early stage (Stage I/II) have a better prognosis (5-year survival rate of
85%-98%). In contrast, patients diagnosed with advanced breast cancer (Stage III/IV) have a
poor 5-year survival rate of 30%-70% [2]. Therefore, some intervention programmes have
been initiated aiming for early diagnosis and treatment of breast cancer to reduce mortality
and improve disease outcomes [3, 4].
Although the case for earlier diagnosis with respect to outcomes has been well made, the
financial implications are less well understood [5, 6]. Stage of disease at diagnosis is an impor-
tant predictor of treatment costs. Treatment for more advanced disease is often more intensive
or invasive than treatment for the earlier stages [5]. As a result, a more advanced stage tends to
be associated with more resource utilisation in addition to poorer health outcomes [7].
Treatment costs by stage at diagnosis are important in quantifying the gains from early
detection. If early treatment lowers costs, this will help offset the cost of interventions for ear-
lier diagnosis and treatment. In addition, treatment costs by stage would be valuable to inform
the cost-effectiveness studies for treatment or preventative interventions of breast cancer.
However, the mean costs by stage do not reveal the heterogeneity across patients. Patient level
data can contain information such as socioeconomic group, medical history, and treatment
options, thus allowing the comparison of costs across patient subgroups and identification of
cost predictors. Therefore, availability of detailed patient level costing data by stage at diagnosis
is important.
To date, no review has directly compared the methods used for collecting and analysing
treatment costs of breast cancer across different settings. A systematic review, published in
2009, aimed to synthesize treatment costs of breast cancer per patient in the United States
(US) [8]. However, this review did not assess between-study methodological differences, such
as cost data collection methods, regression models, or whether breast cancer-attributable costs
were estimated. Differences in methods should be examined, however, because they might
have affected the cost estimates of breast cancer treatment.
In this paper, we undertook a systematic review of breast cancer treatment costs by stage at
diagnosis based on patient level data to: (i) compare stage-specific treatment costs across
A systematic review of breast cancer costs
PLOS ONE | https://doi.org/10.1371/journal.pone.0207993 November 26, 2018 2 / 14
countries at different levels of socio-economic development; and (ii) identify key methodologi-
cal differences in costing approaches.
Materials and methods
Eligibility criteria
This study has been registered in PROSPERO international prospective register of systematic
review (CRD42018097473). The inclusion criteria were based on the PICOS framework: (i)
population: female breast cancer patients; (ii) intervention: any form of clinical treatment
interventions; (iii) comparator: not restricted; (iv) outcome: direct medical treatment costs
(inpatient and outpatient) by stage incurred in hospital settings at the patient level; and (v)
study design: costing studies with primary data.
We excluded studies with the following characteristics: (i) no treatment cost estimates by
stage; (ii) treatment costs not incurred in hospital settings which cannot reflect direct medical
costs (inpatient and outpatient); (iii) costs not estimated from actual patient level data, but cal-
culated according to treatment pathways in clinical guidelines; (iv) disease stages categorised
neither as 0, I, II, III and IV in the International Federation of Gynaecology and Obstetrics
(FIGO) staging system, nor as in situ, local, regional and distant cancer; and (v) review articles.
Only studies that had primary data on the breast cancer costs were selected to avoid repeating
previously published information. There was no language limit for the eligibility criteria.
Search methods
We searched MEDLINE(R) (1946 to April Week 4 2018), EMBASE Classic + EMBASE (1947
to 30 April 2018), and NHS Economic Evaluation Database (NHS EED, 1960 to April 2018)
with search terms in S1 Table. Also, reference lists from relevant primary studies and review
articles were used to identify other relevant publications. Titles and abstracts were first
reviewed, and full-texts of the studies that potentially met the eligibility criteria were retrieved
and full-text reviewed.
Data extraction
Two investigators independently extracted the study characteristics and treatment costs of
breast cancer by stage at diagnosis. Most studies conducted cost analyses up to a specified time
rather than over a lifetime horizon. Although some studies reported the annual costs, we
extracted the cumulative costs during the pre-specified time horizons for comparative pur-
poses. We first summarised the cumulative treatment costs of breast cancer patients by stage
in all reviewed studies. Then we compared the costs in studies with the same pre-specified
time horizons.
We used US dollars with the base year of 2015 to facilitate the comparison of costs. In this
study, we used purchasing power parity (PPP) conversion factor to convert cost estimates
reported in different currencies to US dollars, and used the consumer price index (CPI) for
health care to convert cost estimates reported at different time points to the same year. PPP is
the rate of currency conversion at which a given amount of currency will purchase the same
volume of goods and services in two countries. CPI is a measure that examines the changes in
the price level of a basket of consumer goods and services.
Critical appraisal and methodological assessment
Two investigators used an established checklist by Drummond et al. [9] to assess the quality of
reviewed studies independently. Items not applicable to costing studies were removed. A
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three-point response scale was added to better grade the quality of each item on the checklist,
ranging from 0 (not considered), through 1 (partially considered), to 2 (fully considered) [10].
We summed up all scores and compared this with the maximum attainable score to calculate
the percentage of the maximum attainable score.
In addition, we conducted a more detailed analysis of the methods used, including whether
costs were based on charges or claims, the data collection approaches, use of control groups,
descriptive analysis of mean costs by stage, regression model choices, censored data analysis,
missing data analysis, and timing issues.
We distinguished between whether charges or claims were used because charges are often
higher than the insurer claim costs [8], though either of which does not necessarily reflect the
true economic costs of providing the medical services.
Costing data collection methods should depend on the aim of the study and the availability
of data [11]. One method is the ingredient approach, also called micro-costing, with resources
and the associated unit costs directly measured. At the other end of the spectrum is the gross
costing or top-down method. In this approach, the costs are usually estimated by reference
costs from a non-patient-specific source [12]. Gross costing is faster and cheaper but may lead
to low accuracy because of the relatively large measurement units. Micro-costing is more reli-
able but may be expensive and not always practical [11].
Non-breast cancer controls were included in some studies. The costs among patients often
incorporate some costs incurred jointly with other diseases or interventions, leading to the
overestimation of the disease-specific costs. By comparing costs of breast cancer cases to con-
trol groups without breast cancer, breast cancer-attributable treatment costs can be estimated.
Description of mean costs by stage was reported in all studies. Some presented only point
estimates, while others also reported the uncertainty of mean values, such as standard errors
and confidence intervals.
Different regression models have been developed for cost modelling to approach the issues
of cost data, such as the skewness, zero-values, and censoring [13]. In general, in cases of no
censoring and no zero-costs, the log-gamma generalised linear model (GLM) is favoured,
which deals with non-normality and avoids back-transformation issues [14]. Regarding the
zero-cost issues, the two-part mixed model is the most informative by showing the possibility
of any expenditure first. For the censoring issues, a regression model can be used which is
weighted by the probability of not being censored. There is no unique model that can deal
with all the problems, and the final choice depends on the type and design of the study.
Missing data could reduce the representativeness of samples and therefore distort infer-
ences about the population. So we summarised the methods of dealing with missing data in
the reviewed studies. Also, we assessed whether cost calculations were adjusted for inflation or
any other changes.
Results
Search results
The search took place in April 2018. MEDLINE search yielded 99 possible studies, EMBASE
yielded 268, NHS EED yielded 32, and hand-searches produced seven from reference lists. The
collective searches yielded 293 unique studies after removing duplicates. Based on the eligibil-
ity criteria, we excluded 273 studies and included 20 studies in this review (Fig 1). The two
reviewers were in complete agreement for study eligibility. The identified studies were from
ten countries: the US (n = 9), Canada (n = 2), China (n = 2), Italy (n = 1), Portugal (n = 1), the
United Kingdom (UK) (n = 1), Vietnam (n = 1), France (n = 1), Iran (n = 1) and Mexico
(n = 1).
A systematic review of breast cancer costs
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Treatment costs of breast cancer by stage
Table 1 summarises basic characteristics and cumulative treatment cost estimates by stage
reported in the reviewed studies, with 85% agreement by two reviewers. Among the 15 studies
using the FIGO staging system, the means of cumulative treatment costs weighted by sample
sizes were $29,724 at stage I, $39,322 at stage II, $57,827 at stage III, and $62,108 at stage IV in
2015 US dollars. On average, costs at stage II, III and IV were 32%, 95%, and 109% higher than
costs at stage I. In the other five studies where invasive breast cancer was categorised as local,
regional and distant, the cost means weighted by sample sizes were $63,664, $89,898 and
$168,906. Treatment costs of regional and distant breast cancer were 41% and 165% higher
than local breast cancer on average. Figs 2 and 3 show that mean treatment costs generally
increased with advanced stage at diagnosis.
The study by Riley et al. was not considered when we calculated the weighted mean values
due to the unknown sample size [33]. This study reported that the lifetime payments between
diagnosis and death were higher for patients diagnosed at an earlier stage, due to higher costs
corresponded to longer survival time. However, they found that the annual average costs for
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0207993.g001
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patients diagnosed at earlier stages were substantially lower than annual costs at advanced
stages. This supported the finding that earlier diagnosis lowers treatment costs.
We should be cautious when synthesising these treatment costs because the time horizons
in the reviewed studies are different. Therefore, we also compared the cumulative treatment
costs during the same time horizons. Four studies reported two-year cumulative treatment
costs after diagnosis by FIGO stages among breast cancer patients. After conversion to 2015
US dollars, the costs estimated by Blumen et al. in the US [18] are much higher than the costs
estimated in Italy [16], Portugal [18], and Canada [19]. The participants in Blumen’s study
were commercially insured population, and they probably sought for more health services
than populations with publically funded insurance.
Two other studies estimated five-year cumulative costs after diagnosis, with the study in
China [22] reporting higher costs than the study in Vietnam [23]. The costs of breast cancer
treatment in Vietnam were much lower than those reported in other countries, due to the lim-
ited use of new medications and advanced medical equipment during the study period [23].
The lack of affordable access to appropriate treatment of breast cancer also contributes to the
low treatment costs. Some patients did not complete their treatment courses because they were
not covered by insurance. In addition, the unit costs can be different across countries, such as
the differences in remuneration of health staff and capital depreciation [23].
Two studies also reported the treatment costs at four years after diagnosis. The costs esti-
mated by Legorreta et al. in the US [21] were higher than those estimated by Wolstenholme
et al. in the UK [20]. However, both studies were conducted about thirty years ago and hence
they were not very informative for the present comparison.
Table 1. Basic characteristics and cumulative breast cancer treatment costs by stage (US dollars in 2015).
Study Setting Sample Year Time horizon Costs by stage
0 I II III IV
Allaire et al, 2017 [15] US 4,082 2003–2010 1y ad1 - 54,664 102,528 127,444
Capri et al, 2017 [16] Italy 12,580 2007–2011 2y ad1 - 12,187 14,541 15,108 17,339
Harfouche et al, 2017 [17] Portugal 807 2014 2y ad1 6,564 10,380 16,667 20,257 24,758
Blumen el al, 2016 [18] US 8,360 2010 2y ad1 81,181 109,582 180,001 206,207
Mittmann et al, 2014 [19] Canada 39,655 2005–2009 2y ad1 - 25,969 40,676 56,703 57,794
Wolstenholme el al, 1998 [20] UK 137 1991 4y ad1 - 8,638 9,652 9,459 15,918
Legorreta el al, 1996 [21] US 200 1989–1993 4y ad1 41,546 50,998 63,308 - -
Li el al, 2013 [22] China 316 2009–2010 5y ad1 10,296 32,884 41,632 44,595 44,766
Hoang Lan el al, 2013 [23] Vietnam 160 2001–2006 5y ad1 - 654 1,038 939 694
Laas E et al, 2012 [24] France 62 2010 Ac2 - 14,817 13,553 - -
Will el al, 2000 [25] Canada 17,700 1995 lifetime - 25,755 28,392 35,628 40,212
Farley el al, 2015 [26] US 274 2008–2010 Unk3 - 27,288 49,680 78,670 -
Davari el al, 2013 [27] Iran 467 2005–2010 Unk3 - 12,838 13,734 20,035 23,643
Meneses-Garcia el al, 2012 [28] Mexico 633 2004 Unk3 - 8,146 9,819 12,586 12,988
Liao et al, 2017 [29] China 2,746 2012–2014 Unk3 - 6,706 6,794 8,556 12,840
In situ Local Regional Distant
Tollestrup el al, 2001 [30] US 317 1990–1994 1y ad1 10,219 14,824 26,502
Subramanian el al, 2011 [31] US 848 2002–2004 2y ad1 31,033 83,455 154,145 320,655
Fireman el al, 1997 [32] US 886 1987–1991 15y ad1 - 67,778 87,921 74,616
Riley el al, 1995 [33] US Unk3 1973–1989 lifetime 164,727 143,367 130,472 85,128
Taplin el al, 1995 [34] US 2,944 1990–1991 Unk3 47,783 61,985 78,814 -
Ad1 indicates after diagnosis, ac2: after chemotherapy, unk3: unknown.
https://doi.org/10.1371/journal.pone.0207993.t001
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Critical appraisal and methodological assessment
The quality of reviewed studies is presented in Table 2, as indicated by the percentage score
ranging from 50% to 84%. Studies by Hoang Lan et al. [23] and Fireman et al. [32] had rela-
tively high total scores among the reviewed papers. Studies scored relatively poorly on data col-
lection items compared to other items. In addition, the choice of regression model was
Fig 2. Cumulative breast cancer treatment costs by FIGO stages.
https://doi.org/10.1371/journal.pone.0207993.g002
A systematic review of breast cancer costs
PLOS ONE | https://doi.org/10.1371/journal.pone.0207993 November 26, 2018 7 / 14
Fig 3. Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.
https://doi.org/10.1371/journal.pone.0207993.g003
Table 2. Critical appraisal scores (percentages of maximum attainable scores).
Studies Scored domains Summary scores
Study design Data collection Analysis and interpretation
Allaire et al, 2017 [15] 6 (100%) 6 (38%) 10 (63%) 22 (58%)
Capri et al, 2017 [16] 6 (100%) 9 (56%) 8 (50%) 23 (61%)
Harfouche et al, 2017 [17] 6 (100%) 8 (50%) 8 (50%) 22 (58%)
Blumen, et al., 2016 [18] 5 (83%) 7 (44%) 8 (50%) 20 (53%)
Mittmann, et al., 2014 [19] 6 (100%) 6 (38%) 16 (100%) 28 (74%)
Wolstenholme et al., 1998 [20] 4 (67%) 8 (50%) 16 (100%) 28 (74%)
Legorreta et al., 1996 [21] 4 (67%) 9 (56%) 16 (100%) 29 (76%)
Li, et al., 2013 [22] 6 (100%) 12 (75%) 10 (63%) 28 (74%)
Hoang Lan et al., 2013 [23] 6 (100%) 10 (63%) 16 (100%) 32 (84%)
Laas E et al, 2012 [24] 6 (100%) 14 (88%) 9 (56%) 29 (76%)
Will, et al., 2000 [25] 4 (67%) 6 (38%) 14 (88%) 24 (63%)
Farley, et al., 2015 [26] 6 (100%) 7 (44%) 6 (38%) 19 (50%)
Davari et al., 2013 [27] 6 (100%) 6 (38%) 15 (94%) 27 (71%)
Meneses-Garcia el al, 2012 [28] 5 (83%) 6 (38%) 14 (88%) 25 (66%)
Liao et al, 2017 [29] 6 (100%) 8 (50%) 7 (44%) 21 (55%)
Tollestrup et al, 2001 [30] 5 (83%) 10 (63%) 14 (88%) 29 (76%)
Subramanian et al, 2011 [31] 5 (83%) 10 (63%) 8 (50%) 23 (61%)
Fireman et al, 1997[32] 5 (83%) 9 (56%) 16 (100%) 30 (79%)
Riley et al, 1995 [33] 5 (83%) 6 (38%) 12 (75%) 23 (61%)
Taplin et al, 1995 [34] 5 (83%) 9 (56%) 12 (75%) 26 (68%)
Average (Kappa = 0.69) 5.4 (89.2%) 8.3 (51.9%) 11.8 (73.4%) 25.4 (66.8%)
https://doi.org/10.1371/journal.pone.0207993.t002
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generally rarely justified. Table 3 summarises other aspects of the methodological assessment,
with detailed study-specific results provided in S2 Table.
Charges/claims. Among the identified studies, nine studies used billed charges to mea-
sure costing data [20, 22, 23, 27–30, 32, 34], ten used claim datasets[15–19, 21, 24, 26, 31, 33],
and one study did not provide information about this [25].
Cost collection and control groups. Fifteen studies used the micro-costing approach to
measure and value cost [15–20, 23–25, 27, 28, 30–33]. However, they did not report the quanti-
ties of resource use separately from the unit costs. Five studies used the gross-costing approach
to collect data [21, 22, 26, 29, 34]. Six studies included control groups to estimate the breast
cancer-attributable treatment costs [15, 19, 30–32, 34].
Descriptive analysis. All of the reviewed studies estimated the means of breast cancer
treatment costs in descriptive analyses. Fourteen studies among these also reported the uncer-
tainty of estimated means [15, 19, 20, 22–24, 27–34], such as standard errors, 95% confidence
intervals, or ranges between the minimum and maximum values.
Regression models. Ten studies used regression models to analyse the breast cancer treat-
ment costs [16, 20–24, 30–32, 34]. Common parametric tests were conducted in six studies.
Fireman et al. [32] used ordinary least squares (OLS) to analyse the relationship between
patient characteristics and treatment costs. Three studies by Legorreta et al. [21], Wolsten-
holme et al. [20], and Li et al. [22] used analysis of variance (ANOVA) to examine differences
in estimated costs across stages at diagnosis. Legorreta et al. [21] also used Chi-square test to
evaluate the association between disease stage at diagnosis and other covariate variables. Taplin
et al. [34] conducted multivariable regression for analysis, but the details of the models used
were not explained.
Parametric approaches may sacrifice robustness when the assumptions of normality or
homoscedasticity are violated. To deal with the large mass of observations with zero costs, Sub-
ramanian et al. [31] used the two-part model. In the first part, a logistic regression was con-
ducted to predict the possibility of any expenditure. In the second part, the generalised linear
model with a gamma distribution and a log link was used conditional on having positive
Table 3. Methodological assessment of the reviewed studies: frequency and percentage.
Charges/claim Billed charges Claim data Unknown
9 (45%) 10 (50%) 1 (5%)
Cost collection Micro costing Gross costing
15 (75%) 5 (25%)
Control groups Yes No
6 (30%) 14 (70%)
Descriptive analysis Only mean Mean and uncertainty
6 (30%) 14 (70%)
Regression models Parametric Tobit Two-part GLM Quantile None
6 (30%) 1 (5%) 1 (5%) 1 (5%) 1 (5%) 10 (50%)
Censored data Described Described
1 (5%) 19 (95%)
Missing data Imputation CCA1 Assumption Not mentioned
1 (5%) 9 (45%) 1 (5%) 9 (45%)
Timing issues Yes No
16 (80%) 4 (20%)
CCA1 indicates complete case analysis.
https://doi.org/10.1371/journal.pone.0207993.t003
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expenditures. Tollestrup et al. [30] considered a Tobit regression model which allowed a point
mass at zero but assumed an underlying normal distribution [35]. Also, Capri et al. [16] used a
generalised linear model to identify predictors of log-transformed costs. In addition to the esti-
mation of mean costs, Hoang Lan et al. [23] used the quantile regression aiming at estimating
the conditional medians of costs.
Censored data. Meneses-Garcia el al. performed analysis of censored-data costs though
no details were described [28]. In the other 19 studies, there was no mention to the approaches
used to deal with censored observations.
Missing data. Only one study dealt with missing data by multiple imputation [20]. Nine
studies conducted complete-case analysis [16, 17, 19, 23, 26–29, 34] and another made
assumptions about the incomplete information [24]. In the remaining studies, there was no
mention to the issue of missing data.
Timing issues. Sixteen studies considered timing issues such as using consumer price
index (CPI) for inflation or discounting the cost values to reflect time preferences. In the other
four studies [18, 22, 26, 28], timing issues were not described.
Discussion
This study systematically reviewed published studies on breast cancer treatment costs by stage
at diagnosis using patient level data from countries at different levels of socio-economic devel-
opment. The review highlighted the fact that published data on this topic are rather limited
and predominantly from high-income countries, and among the latter predominantly from
the US. Of the 20 eligible studies identified, nine were from the US and only five from low-
and middle-income countries. In addition, many of the studies were very dated. The paucity of
the published evidence reflects in part the limited availability of staging information. The
WHO International Classification of Diseases (ICD), which is the international standard used
for reporting diseases and health conditions in routinely collected data, does not include codes
for the stage at cancer diagnosis. Therefore, acquisition of stage information usually requires
the collection of additional data from other (non-routine) sources or needs to be inferred from
recommended stage-specific treatment protocols, neither of which is always feasible. It is
worthwhile noting that the present review excluded studies that used a combination of clinical
guidelines and unit costs, instead of patient level data, to estimate treatment costs as such cost
estimates cannot reveal between-patient heterogeneity [36]. The review also excluded any data
published in the grey literature by design, e.g. governmental reports, as its search was restricted
to the scientific peer-reviewed literature. As studies with unfavourable results are less likely to
be published, publication bias can be a potential concern for this review.
Nevertheless, the review’s findings are consistent with treatment costs increasing with the
advancement of the disease stage at diagnosis. The mean treatment costs of stages II, III and
IV breast cancer were 32%, 95%, and 109% higher than those of stage I disease, and the mean
treatment costs of regional and distant breast cancer were 41% and 165% higher than those of
local disease. It has been shown that patients with more advanced disease receive more treat-
ments than early-stage patients, such as chemotherapy and targeted therapy [37]. Also, medi-
cation therapy is usually a costly part of treatment for patients at stages III and IV because of
the prescription of more expensive drugs [27, 38, 39].
The review revealed between-country differences in treatment costs, with these likely to be
partly due to the variation in treatment patterns. For example, the UK used human epidermal
growth factor receptor 2 (HER2)-targeted medicine the least frequently among five European
Union countries [40]. The US uses three times as many mammograms compared to other
developed countries [41]. Also, the high administrative costs and drug costs in the US make
A systematic review of breast cancer costs
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the breast cancer treatment costs higher there than in many other high-income countries.
Between-country differences in treatment costs might have also arisen because breast cancer
survival rates vary widely across countries, overall ranging from 80% or over in North America
to around 60% in middle-income countries and below 40% in low-income countries [42]. This
reflects partly differences in stage at diagnosis as well as variations in the availability and access
to appropriate treatments.
The review also revealed within-country variations in the treatment costs of breast cancer
for the two countries with more than one study, i.e. the US, Canada, and China. Such differ-
ences may be partly due to differences in the years covered, i.e. the years of breast cancer diag-
nosis, as well as variations in time horizons. Advances in medicine have led to temporal
changes in therapy strategies for breast cancer. Nowadays, breast conservation is the intended
surgical standard approach for most women with early breast cancer [43]. Also, more system-
atic therapies have become available, such as endocrine therapy for hormone receptor positive
breast cancer and target therapy for HER2-positive breast cancer [44].
The methodological assessment of the reviewed studies highlighted key methodological
concerns. First, studies that used micro-costing approaches to collect cost data did not report
the quantities of resources separately from the unit costs. Second, regression frameworks var-
ied across studies. Some used common parametric tests such as ANOVA and OLS regression
for cost estimations; however, these tests could be inappropriate due to the violation of their
underlying assumptions. Two-part model and Tobit regression were conducted in some stud-
ies to deal with the impact of zero values, generalised linear model was applied to handle skew-
ness, and quantile regression was used to estimate the median of costs. But the choice of these
regression models was not fully justified. Third, only one study considered censored data
though no details were described [28]. Censored data can be caused by death, loss to follow up,
and administrative censoring [13]. If censoring is not accounted, the assessment of the impor-
tance of the disease severity on the cost of treatment may be biased [45]. Finally, the large
majority of studies did not include a control group. Failure to do so might have resulted in an
overestimation of cost values attributable to breast cancer treatment as some of the included
costs might have been incurred by treatment of other co-existing diseases. All these methodo-
logical issues should be better dealt with in future costing studies.
Conclusions
This systematic review highlighted the paucity of published studies on breast cancer treatment
costs by stage, based on patient-level data, from both high-income and low/middle-income
countries. Nevertheless, the limited available data are consistent with earlier detection of breast
cancer being associated with lower treatment costs. More up-to-date studies on treatment
costs of breast cancer by stage are required from beyond the US including other developed and
developing regions. Further costing studies should properly address and clearly describe key
methodological issues (e.g. skewness, zero values, censored data, missing data).
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